84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]羅漫麗,黃滿玉,李東升,等.多種血清腫瘤相關(guān)抗原自身抗體聯(lián)合檢測對(duì)骨肉瘤的診斷價(jià)值研究[J].中醫(yī)正骨,2021,33(04):32-37.
　LUO Manli,HUANG Manyu,LI Dongsheng,et al.A study of the clinical value of combined detection on serum autoantibodies against tumor-associated antigens in the diagnosis of osteosarcomas[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(04):32-37.
點(diǎn)擊復(fù)制

多種血清腫瘤相關(guān)抗原自身抗體聯(lián)合檢測對(duì)骨肉瘤的診斷價(jià)值研究()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第33卷
期數(shù):
2021年04期
頁碼:
32-37
欄目:
臨床研究
出版日期:
2021-04-20

文章信息/Info

Title:
A study of the clinical value of combined detection on serum autoantibodies against tumor-associated antigens in the diagnosis of osteosarcomas
作者:
羅漫麗1; 黃滿玉2; 李東升2; 馬言2; 張勇勇2; 羅亞鴿2; 李記天2; 代麗萍1
(1.鄭州大學(xué)基礎(chǔ)醫(yī)學(xué)院,河南 鄭州 450001; 2.河南省洛陽正骨醫(yī)院/河南省骨科醫(yī)院,河南 鄭州 450016)
Author(s):
LUO Manli1; HUANG Manyu2; LI Dongsheng2; MA Yan2; ZHANG Yongyong2; LUO Yage2; LI Jitian2; DAI Liping1
1.School of Basic Medical Sciences of Zhengzhou University,Zhengzhou 450001,Henan,China2.Luoyang Orthopedic-Traumatological Hospital,Zhengzhou 450016,Henan,China
關(guān)鍵詞:
骨肉瘤;  抗原; 腫瘤;  自身抗體;  診斷;  免疫學(xué)試驗(yàn)
Keywords:
osteosarcoma;  antigens; neoplasm;  autoantibodies;  diagnosis;  immunologic tests
摘要:
目的:探討多種血清腫瘤相關(guān)抗原(tumor associated antigen,TAA)自身抗體聯(lián)合檢測對(duì)骨肉瘤的診斷價(jià)值。方法:收集2013年12月至2016年6月收治的51例骨肉瘤患者(骨肉瘤組)和同時(shí)期在醫(yī)院體檢的51例健康志愿者(健康組)的外周血血清。使用間接ELISA法檢測所有受試對(duì)象血清中抗烯醇化酶1(enolase 1,ENO1)自身抗體、抗甘油醛-3-磷酸脫氫酶(glyceraldehyde-3-phosphate dehydrogenase,GAPDH)自身抗體、抗熱休克蛋白(heat shock protein,HSP)27自身抗體、抗HSP60自身抗體、抗核仁磷酸蛋白1(nucleophosmin 1,NPM1)自身抗體、抗人PDZ和LIM域蛋白1(PDZ and LIM domain 1,PDLIM1)自身抗體、抗重組人微管解聚蛋白1(stathmin 1,STMN1)自身抗體、抗丙糖磷酸異構(gòu)酶1(triosephosphate isomerase 1,TPI1)自身抗體共8種TAA自身抗體的血清含量。按單側(cè)估計(jì)各TAA自身抗體含量的95%參考值范圍,并以此計(jì)算和評(píng)價(jià)各TAA自身抗體血清含量檢測診斷骨肉瘤的價(jià)值。按診斷的靈敏度由高到低排序,從診斷骨肉瘤靈敏度最高的自身抗體開始,每次增加1種靈敏度排名次一位的自身抗體,計(jì)算和評(píng)價(jià)對(duì)應(yīng)的TAA自身抗體聯(lián)合檢測診斷骨肉瘤的價(jià)值。結(jié)果:①2組血清TAA自身抗體含量檢測及對(duì)比結(jié)果。2組受試對(duì)象血清中抗ENO1自身抗體、抗GAPDH自身抗體、抗HSP27自身抗體、抗HSP60自身抗體、抗PDLIM1自身抗體、抗STMN1自身抗體和抗TPI1自身抗體含量比較,組間差異均有統(tǒng)計(jì)學(xué)意義(0.269±0.101,0.202±0.113,Z=-3.758,P=0.000; 0.145±0.037,0.125±0.027,Z=-3.477,P=0.001; 0.175±0.048,0.164±0.027,Z=-2.125,P=0.034; 0.174±0.048,0.149±0.028,Z=-2.871,P=0.004; 0.305±0.079,0.288±0.068,Z=-2.249,P=0.025; 0.188±0.082,0.167±0.071,Z=-2.041,P=0.041; 0.174±0.083,0.159±0.040,Z=-2.095,P=0.036); 2組受試對(duì)象血清中抗NPM1自身抗體含量比較,差異無統(tǒng)計(jì)學(xué)意義(0.255±0.075,0.260±0.064,Z=-0.020,P=0.984)。②血清TAA自身抗體含量檢測診斷骨肉瘤的結(jié)果。除抗NPM1自身抗體之外的7種TAA自身抗體中,抗STMN1自身抗體診斷骨肉瘤的價(jià)值最大,其靈敏度為27.45%、特異度為96.08%、Youden指數(shù)為0.235 3、Kappa值為0.24。隨著聯(lián)合檢測的TAA自身抗體種類增加,診斷的靈敏度逐漸增大、特異度逐漸減小。當(dāng)聯(lián)合檢測抗STMN1自身抗體、抗TPI1自身抗體、抗PDLIM1自身抗體、抗ENO1自身抗體和抗HSP27自身抗體5種血清TAA自身抗體時(shí),診斷效果比較理想,對(duì)應(yīng)的靈敏度為60.78%、特異度為80.39%、Youden指數(shù)為0.411 8、符合率為70.59%、Kappa值為0.41。結(jié)論:聯(lián)合檢測抗STMN1自身抗體、抗TPI1自身抗體、抗PDLIM1自身抗體、抗ENO1自身抗體和抗HSP27自身抗體5種血清TAA自身抗體,對(duì)骨肉瘤具有較高的診斷價(jià)值。
Abstract:
To explore the clinical value of combined detection on serum autoantibodies against tumor associated antigens(TAA)in the diagnosis of osteosarcomas(OSs).Methods:The peripheral serum samples were collected from 51 OSs patients(OSs group)recruited from December 2013 to June 2016 and 51 healthy volunteers(healthy group)undergoing medical examination during the same period respectively.The serum levels of autoantibodies,including anti-enolase 1(anti-ENO1),anti-glyceraldehyde-3-phosphate dehydrogenase(anti-GAPDH),anti-heat shock protein 27(anti-HSP27),anti-HSP60,anti-nucleophosmin 1(anti-NPM1),anti-PDZ and LIM domain 1(anti-PDLIM1),anti-stathmin 1(anti-STMN1)and anti-triosephosphate isomerase 1(anti-TPI1),were detected by using indirect enzyme-linked immunoadsordent assay(ELISA).The clinical value of detection on the serum level of each anti-TAA autoantibody for diagnosis of OSs was calculated and evaluated based on the 95% reference range of the serum level of each anti-TAA autoantibody estimated unilaterally.According to the sort by diagnostic sensitivity from highest to lowest,starting from the autoantibody with the highest sensitivity in the diagnosis of OSs,one autoantibody with the next highest sensitivity was added each time,and the value of combined detection on corresponding anti-TAA autoantibodies in diagnosis of OSs was calculated and evaluated.Results:There were statistical difference in the serum levels of anti-ENO1,anti-GAPDH,anti-HSP27,anti-HSP60,anti-PDLIM1,anti-STMN1 and anti-TPI1 autoantibodies between the 2 groups(0.269±0.101 vs 0.202±0.113,Z=-3.758,P=0.000; 0.145±0.037 vs 0.125±0.027,Z=-3.477,P=0.001; 0.175±0.048 vs 0.164±0.027,Z=-2.125,P=0.034; 0.174±0.048 vs 0.149±0.028,Z=-2.871,P=0.004; 0.305±0.079 vs 0.288±0.068,Z=-2.249,P=0.025; 0.188±0.082 vs 0.167±0.071,Z=-2.041,P=0.041; 0.174±0.083 vs 0.159±0.040,Z=-2.095,P=0.036).There was no statistical difference in the serum level of anti-NPM1 autoantibody between the 2 groups(0.255±0.075 vs 0.260±0.064,Z=-0.020,P=0.984).The anti-STMN1 autoantibody presented with the maximum value in diagnosis of OSs among anti-ENO1,anti-GAPDH,anti-HSP27,anti-HSP60,anti-PDLIM1,anti-STMN1 and anti-TPI1 autoantibodies,with the sensitivity,specificity,Youden index and Kappa value as 27.45%,96.08%,0.235 3 and 0.24 respectively.With the increase of the number of anti-TAA autoantibodies,the diagnostic sensitivity gradually increased and the diagnostic specificity gradually decreased.The diagnostic effects were optimal when the combined detection was performed on serum autoantibodies of STMN1,TPI1,PDLIM1,ENO1 and HSP27 with the corresponding sensitivity,specificity,Youden index,total consistent rate and Kappa value as 60.78%,80.39%,0.4118,70.59% and 0.41 respectively.Conclusion:The combined detection on serum autoantibodies of STMN1,TPI1,PDLIM1,ENO1 and HSP27 enjoys high clinical value in diagnosis of OSs.

參考文獻(xiàn)/References:

[1] WARD E,DESANTIS C,ROBBINS A,et al.Childhood and adolescent cancer statistics,2014[J].CA Cancer J Clin,2014,64(2):83-103.
[2] JAFARI F,JAVDANSIRAT S,SANAIE S,et al.Osteosarcoma:a comprehensive review of management and treatment strategies[J].Ann Diagn Pathol,2020,49:151654.
[3] WANG K,LI M,QIN J,et al.Serological biomarkers for early detection of hepatocellular carcinoma:a focus on autoantibodies against tumor-associated antigens encoded by cancer driver genes[J].Cancers(Basel),2020,12(5):1271.
[4] QIN J,WANG S,SHI J,et al.Using recursive partitioning approach to select tumor-associated antigens in immunodiagnosis of gastric adenocarcinoma[J].Cancer Sci,2019,110(6):1829-1841.
[5] MA Y,WANG X,QIU C,et al.Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer[J].Cancer Sci,2021,112(2):537-549.
[6] JIANG D,WANG Y,LIU M,et al.A panel of autoantibodies against tumor-associated antigens in the early immunodiagnosis of lung cancer[J].Immunobiology,2020,225(1):151848.
[7] ZHANG L,DONG B,REN P F,et al.Circulating plasma microRNAs in the detection of esophageal squamous cell carcinoma[J].Oncol Lett,2018,16(3):3303-3318.
[8] ZAYAKIN P,ANCANS G,SILINA K,et al.Tumor-associated autoantibody signature for the early detection of gastric cancer[J].Int J Cancer,2013,132(1):137-147.
[9] LU H,GOODELL V,DISIS M L.Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer[J].J Proteome Res,2008,7(4):1388-1394.
[10] ANDERSON K S,CRAMER D W,SIBANI S,et al.Auto-antibody signature for the serologic detection of ovarian cancer[J].J Proteome Res,2015,14(1):578-586.
[11] ZHANG H F,QIN J J,REN P F,et al.A panel of autoantibodies against multiple tumor-associated antigens in the immunodiagnosis of esophageal squamous cell cancer[J].Cancer Immunol Immunother,2016,65(10):1233-1242.
[12] WAFA H,GRIMER R J.Surgical options and outcomes in bone sarcoma[J].Expert Rev Anticancer Ther,2006,6(2):239-248.
[13] YANG Q,QIN J,SUN G,et al.Discovery and validation of serum autoantibodies against tumor-associated antigens as biomarkers in gastric adenocarcinoma based on the focused protein arrays[J].Clin Transl Gastroenterol,2020,12(1):e00284.
[14] SUN G,YE H,WANG X,et al.Identification of novel auto-antibodies based on the protein chip encoded by cancer-driving genes in detection of esophageal squamous cell carcinoma[J].Oncoimmunology,2020,9(1):1814515.
[15] ZHAO C,LI H L,WANG L,et al.An immunohistochemical study of stathmin 1 expression in osteosarcoma shows an association with metastases and poor patient prognosis[J].Med Sci Monit,2018,24:6070-6078.
[16] CHEN K,ZHU C,CAI M,et al.Integrative metabolome and transcriptome profiling reveals discordant glycolysis process between osteosarcoma and normal osteoblastic cells[J].J Cancer Res Clin Oncol,2014,140(10):1715-1721.
[17] GUPTA P,SUMAN S,MISHRA M,et al.Autoantibodies against TYMS and PDLIM1 proteins detected as circulatory signatures in Indian breast cancer patients[J].Proteomics Clin Appl,2016,10(5):564-573.
[18] MOON A,BACCHINI P,BERTONI F,et al.Expression of heat shock proteins in osteosarcomas[J].Pathology,2010,42(5):421-425.
[19] GAO S S,WANG Y J,ZHANG G X,et al.Potential diagnostic value of miRNAs in peripheral blood for osteosarcoma:a meta-analysis[J].J Bone Oncol,2020,23:100307.
[20] WANG P,QIN J,YE H,et al.Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer[J].J Cell Biochem,2019,120(3):3091-3100.
[21] ZHANG L,WANG H,DONG X.Diagnostic value of α-enolase expression and serum α-enolase autoantibody levels in lung cancer[J].J Bras Pneumol,2018,44(1):18-23.
[22] WANG S,QIN J,YE H,et al.Using a panel of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of gastric cancer[J].Oncoimmunology,2018,7(8):e1452582.

相似文獻(xiàn)/References:

[1]于雅麗,王雷鳴.二氯乙酸鈉對(duì)人骨肉瘤MG63細(xì)胞增殖、凋亡和遷移的影響[J].中醫(yī)正骨,2017,29(01):11.
　YU Yali,WANG Leiming.Effect of sodium dichloroacetate on cell proliferation,apoptosis and migration in human MG63 osteosarcoma cells[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(04):11.
[2]羅明星,劉丙根,羅文禮,等.保肢與截肢治療后骨肉瘤患者肢體功能及生活質(zhì)量的Meta分析[J].中醫(yī)正骨,2017,29(07):41.
　LUO Mingxing,LIU Binggen,LUO Wenli,et al.Comparison of limb salvage and amputation on limb function and life quality of patients with osteosarcoma:a meta analysis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(04):41.
[3]丁聚賢,謝興文,許偉,等.中醫(yī)藥在骨肉瘤放化療中的作用研究進(jìn)展[J].中醫(yī)正骨,2018,30(05):43.
[4]劉柏良,秦瑨,劉小榮,等.miR-27a參與骨肉瘤發(fā)生發(fā)展作用機(jī)制的研究進(jìn)展[J].中醫(yī)正骨,2025,37(03):53.

備注/Memo

備注/Memo:
基金項(xiàng)目:河南省中醫(yī)藥科學(xué)研究專項(xiàng)課題(2018ZYZD01); 2019年洛陽市科技計(jì)劃醫(yī)療衛(wèi)生項(xiàng)目(1930005A)
通訊作者:代麗萍 E-mail:[email protected]
更新日期/Last Update: 1900-01-01